Theradaptive is a privately held, clinical-stage biologics company in Frederick, Maryland developing engineered protein therapeutics for spine, orthopedic, dental and soft tissue repair, plus targeted immuno-oncology. Its core AMP2 platform re-engineers naturally occurring proteins so they bind to an implant or graft material and stay where they are placed, delivering a sustained, localized regenerative signal rather than diffusing into surrounding tissue. The company says it has produced hundreds of material-binding variants of recombinant proteins across more than a dozen clinical indications. It was founded by Luis Alvarez, a retired U.S. Army officer and MIT-trained protein engineer who conceived the platform after a combat tour in Iraq.